3 Top Diagnostic Stocks to Watch for Future Multibagger Potential: Dr Lal PathLabs, Vijaya Diagnostic and Metropolis
- October 16, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Dr Lal PathLabs Rs 1,880. Vijaya Diagnostic Rs 1,387.40. Metropolis Rs 535. Market caps from Rs 10,875 crore to Rs 31,675 crore. Data as of 16 Oct 2026.
Quick Answer
Dr Lal PathLabs, Vijaya Diagnostic and Metropolis are the 3 picks in this diagnostic stocks watchlist, with market caps between Rs 10,875 crore and Rs 31,675 crore. Dr Lal PathLabs stands out for the highest return on equity at 20.13%, while Vijaya Diagnostic offers the fastest profit growth, 11.81% a year since FY22. PE ratios run from 53.60 to 75.90, so compare each one with its industry PE before investing. All figures are as of 16 October 2026.
Diagnostic stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Dr Lal PathLabs, Vijaya Diagnostic and Metropolis meet that test, with market caps from Rs 10,875 crore to Rs 31,675 crore and Dr Lal PathLabs offering the highest return on equity at 20.13%. Preventive health checks and doctor-prescribed tests are growing, and organised diagnostic chains are taking share from small local labs.
This list covers listed diagnostic chains with complete, verifiable financials, ranked by market capitalisation. Not every name here is a largecap, so the list takes the leading companies of the sector by market capitalisation. Investors screening diagnostic stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Diagnostic Stocks and Why Do They Attract Multibagger Interest?
Diagnostic stocks are listed companies that run pathology laboratories, radiology centres and sample collection networks. They earn a fee for every test, so revenue grows with the number of patients, the tests per patient and the price per test.
Rising health awareness, insurance cover and lifestyle-disease screening support test volumes, while quality accreditation and brand trust help chains win business from unorganised labs. Companies that add collection centres without raising costs at the same pace are the ones investors favour in diagnostic stocks.
Diagnostic Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are as of 16 October 2026, mid-session. Metropolis has the lowest PE of the group at 53.60, while Dr Lal PathLabs posts the highest return on equity at 20.13%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Dr Lal PathLabs | 1,880 | 31,675 | 57.98 | 60.75 | 20.13% | 0.08 | 1,272.60 to 2,038.60 |
| Vijaya Diagnostic Centre | 1,387.40 | 14,228 | 75.90 | 60.75 | 18.07% | 0.44 | 848.00 to 1,593.60 |
| Metropolis Healthcare | 535 | 10,875 | 53.60 | 60.75 | 12.56% | 0.15 | 453.50 to 733.00 |
Dr Lal PathLabs: Return on Equity of 20.13%
Dr Lal PathLabs is one of India’s leading diagnostic chains, running laboratories and collection centres across the country. It reported FY26 revenue of Rs 2,864.18 crore, up 12.11% year on year, and net profit of Rs 509.75 crore, up 3.56%. Net profit has compounded at 9.83% a year since FY22, while revenue has grown 7.56% a year. Operating margin was 30.90% in FY26. The debt-to-equity ratio is 0.08, which keeps interest costs low.
In the June 2026 quarter, revenue rose 18.87% to Rs 829.60 crore and net profit grew 27.24% to Rs 170.50 crore. The share price is up 19.11% over the past year. Domestic institutions raised their holding from 17.91% in June 2025 to 21.59% in June 2026. The stock trades at a PE of 57.98 against an industry PE of 60.75, below the sector average, with a return on equity of 20.13%.
Vijaya Diagnostic: Quarterly Profit Up 37.60%
Vijaya Diagnostic Centre runs diagnostic centres offering pathology and radiology services, with a strong base in South India. It reported FY26 revenue of Rs 835 crore, up 19.34% year on year, and net profit of Rs 172.98 crore, up 20.30%. Net profit has compounded at 11.81% a year since FY22, while revenue has grown 15.13% a year. Operating margin was 43.94% in FY26. The debt-to-equity ratio is 0.44.
The stock trades at a PE of 75.90 against an industry PE of 60.75, with a return on equity of 18.07%. In the June 2026 quarter, revenue rose 22.76% to Rs 239.51 crore and net profit grew 37.60% to Rs 53.10 crore. The share price has gained 141.31% over five years and 38.44% over the past year. Domestic institutions raised their holding from 25.34% in September 2025 to 32.50% in September 2026.
Metropolis: Revenue Up 24.15% in FY26
Metropolis Healthcare provides pathology and diagnostic services through a network of laboratories, clinical labs and collection centres. It reported FY26 revenue of Rs 1,671.43 crore, up 24.15% year on year, and net profit of Rs 191.18 crore, up 31.39%. Revenue has compounded at 7.62% a year since FY22. Operating margin was 25.63% in FY26. The debt-to-equity ratio is 0.15, which keeps interest costs low.
In the June 2026 quarter, revenue rose 15.69% to Rs 455.32 crore and net profit grew 25.70% to Rs 56.88 crore. Domestic institutions raised their holding from 32.40% in June 2025 to 35.12% in June 2026. The stock trades at a PE of 53.60 against an industry PE of 60.75, below the sector average, with a return on equity of 12.56%.
Diagnostic Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these diagnostic stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Dr Lal PathLabs | 2,864.18 | 509.75 | 12.11% | 7.56% | 18.87% | 35.03% |
| Vijaya Diagnostic | 835 | 172.98 | 19.34% | 15.13% | 22.76% | 46.35% |
| Metropolis | 1,671.43 | 191.18 | 24.15% | 7.62% | 15.69% | 25.83% |
Check the Univest Screener for live data on these diagnostic stocks
Institutional Holding in Dr Lal PathLabs, Vijaya Diagnostic and Metropolis
Institutional holding shows who is backing these diagnostic stocks alongside the promoter. The table uses the latest reported quarter for each. Metropolis has the deepest institutional backing, with FII and DII together holding 46.15% as of June 2026. Domestic institutions increased their holding over the past year in Dr Lal PathLabs (from 17.91% to 21.59%), Vijaya Diagnostic (from 25.34% to 32.50%) and Metropolis (from 32.40% to 35.12%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Dr Lal PathLabs | 53.19% | 17.36% | 21.59% | 7.86% | June 2026 |
| Vijaya Diagnostic | 52.46% | 10.66% | 32.50% | 4.38% | September 2026 |
| Metropolis | 48.86% | 11.03% | 35.12% | 4.99% | June 2026 |
Risks to Weigh in Diagnostic Stocks
Being careful with diagnostic stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Diagnostic chains compete on price and convenience, so test pricing and collection centre economics need watching.
- Many diagnostic names trade at premium PE multiples, so earnings need to keep growing to support the price.
- Valuation: Vijaya Diagnostic trades at a PE of 75.90 against an industry PE of 60.75, so earnings need to keep growing to support the price.
- Concentration: Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Diagnostic Stocks
Picking from diagnostic stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (60.75) and ask whether the growth rate justifies any gap.
- Track test volumes, revenue per patient and the operating margin each quarter, because they show how well each chain uses its network.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs, Vijaya Diagnostic and Metropolis live prices.
Conclusion
Among diagnostic stocks, Dr Lal PathLabs stands out for the highest return on equity at 20.13%, Vijaya Diagnostic for the fastest profit growth, 11.81% a year since FY22 and Metropolis for the lowest PE of the group at 53.60. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing diagnostic stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Diagnostic Stocks to Watch
Which are the best diagnostic stocks to watch for multibagger potential?
Ans. Dr Lal PathLabs, Vijaya Diagnostic and Metropolis are the 3 names this list highlights, with market caps of Rs 31,675 crore, Rs 14,228 crore and Rs 10,875 crore respectively. Dr Lal PathLabs is notable for the highest return on equity at 20.13%. Vijaya Diagnostic stands out for the fastest profit growth, 11.81% a year since FY22. Metropolis offers the lowest PE of the group at 53.60. These are watchlist names for diagnostic stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Dr Lal PathLabs a good stock for long-term investors?
Ans. Dr Lal PathLabs has a return on equity of 20.13%, a PE of 57.98 against an industry PE of 60.75 and a market cap of Rs 31,675 crore. Net profit has compounded at 9.83% a year since FY22, and FY26 revenue rose 12.11% while June 2026 quarter net profit grew 27.24%. Long-term returns in diagnostic stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Vijaya Diagnostic become a multibagger from here?
Ans. Vijaya Diagnostic has already gained 141.31% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in diagnostic stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 11.81% a year since FY22, and FY26 revenue rose 19.34%. At a PE of 75.90 against an industry PE of 60.75, valuation should be checked against that growth before investing.
What is the market cap of Dr Lal PathLabs, Vijaya Diagnostic and Metropolis?
Ans. As of 16 October 2026, Dr Lal PathLabs has a market cap of Rs 31,675 crore, Vijaya Diagnostic has a market cap of Rs 14,228 crore and Metropolis has a market cap of Rs 10,875 crore. Dr Lal PathLabs is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on diagnostic stocks.
What are the risks of investing in diagnostic stocks?
Ans. The main risks are pricing competition, valuation and the pace of network expansion. New collection centres take time to break even, and several diagnostic stocks trade at premium PE ratios. Staggering purchases and following quarterly volume trends helps manage this. Vijaya Diagnostic trades at a PE of 75.90 against an industry PE of 60.75, so earnings growth needs to hold up.
Why is Vijaya Diagnostic trading at a PE of 75.90?
Ans. Vijaya Diagnostic’s PE of 75.90 compares with an industry PE of 60.75. The market is paying a premium for a return on equity of 18.07%, profit growth of 11.81% a year since FY22 and latest-quarter profit growth of 37.60%, which also means the stock is more sensitive if growth slows. Investors in diagnostic stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Dr Lal PathLabs, Vijaya Diagnostic and Metropolis?
Ans. As of the latest reported quarter, FII and DII together hold 38.95% of Dr Lal PathLabs (17.36% and 21.59%), 43.16% of Vijaya Diagnostic (10.66% and 32.50%) and 46.15% of Metropolis (11.03% and 35.12%). Rising institutional holding is a useful signal in diagnostic stocks, though it should be read with earnings trends rather than on its own.
